Retatrutide 20mg

Retatrutide, a groundbreaking medication developed by Eli Lilly, shows immense promise for treating obesity and diabetes. Also known as GGG Tri-agonist, GLP-1/GIP/glucagon tri-agonist, or LY3437943, this injectable drug offers enhanced efficacy compared to existing weight loss treatments like tirzepatide and semaglutide. When combined with a healthy diet, regular exercise, and lifestyle changes, retatrutide can significantly improve weight loss outcomes and address obesity-related conditions such as diabetes and hypertension.

How Does Retatrutide Work?

Retatrutide works through three key mechanisms, making it more effective than many other weight loss medications:

1. GIPR Agonism

   Retatrutide acts on the gastric inhibitory polypeptide receptor (GIPR) to suppress appetite and reduce fat accumulation. This leads to decreased energy intake and increased energy expenditure.

2. GLP-1R Agonism

   By targeting glucagon-like peptide-1 receptors (GLP-1R), retatrutide helps regulate blood sugar levels. It enhances insulin release from the pancreas and reduces glucagon production, contributing to weight loss and better glucose control.

3. GR Agonism

   Through glucagon receptor (GR) agonism, retatrutide minimizes glucagon release, decreases food intake, and boosts energy expenditure, resulting in effective weight reduction.

Retatrutide Clinical Trials

A. Weight Loss Benefits

Retatrutide has demonstrated substantial weight loss potential across multiple trials:

• Phase 2 Trial (New England Journal of Medicine, 2023):

  A 48-week study involving 338 adults with obesity showed the following average weight reductions:

• • 1 mg dose: 8.7%
  • 4 mg dose: 17.1%
  • 8 mg dose: 22.8%
  • 12 mg dose: 24.2%
    (Placebo group: 2.1%)

Participants also experienced improvements in cholesterol levels, blood glucose, insulin sensitivity, and blood pressure.

• Type 2 Diabetes Study:

  Adults with type 2 diabetes who received retatrutide (3/6/9/12 mg) lost an average of 17% of their body weight over nine months, with a favorable safety profile.

• Preclinical Animal Studies:

• • Obese mice treated with retatrutide showed a 45% reduction in body weight through decreased fat mass and appetite suppression.
  • High-fat-fed mice exhibited reduced blood sugar levels and increased insulin concentrations after retatrutide administration.

• Human Studies:

  In a Phase 1 study of 45 healthy individuals, subcutaneous retatrutide led to significant weight loss that was maintained up to 43 days.

B. Improved Blood Sugar Control

Retatrutide enhances blood sugar regulation by boosting insulin release and suppressing glucagon production. Evidence from trials includes:

• Reduced HbA1c (a marker of long-term blood sugar control) in patients with type 2 diabetes.
• Improved insulin sensitivity in obese mice, leading to lower fasting glucose levels.
• Increased fasting insulin and C-peptide levels in human subjects, resulting in better glycemic control.

C. Blood Pressure Reduction

By promoting weight loss, retatrutide indirectly improves blood pressure—a common benefit linked to reduced body fat. Clinical findings include:

• Phase 1 Trial: Participants experienced reductions in systolic blood pressure, which returned to near-baseline by day 29.
• T2D Study: Diabetic patients treated with retatrutide for 12 weeks showed notable decreases in blood pressure alongside weight loss.

Safety and Side Effects

Retatrutide is generally well-tolerated, with side effects similar to other incretin-based therapies. Most adverse events were mild and gastrointestinal in nature, resolving independently. Less common side effects include:

• Chest pain
• Dizziness
• Fatigue
• Headache
• Swelling in extremities

References

1. 1. Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML; Retatrutide Phase 2 Obesity Trial Investigators. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972. Epub ahead of print. PMID: 37366315.
   2. Urva, S., Coskun, T., Loh, M. T., Du, Y., Thomas, M. K., Gurbuz, S., Haupt, A., Benson, C. T., Hernandez-Illas, M., D’Alessio, D. A., & Milicevic, Z. (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet (London, England), 400(10366), 1869–1881. https://doi.org/10.1016/S0140-6736(22)02033-5.
   3. Gault, V. A., Bhat, V. K., Irwin, N., & Flatt, P. R. (2013). A novel glucagon-like peptide-1 (GLP-1)/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice. The Journal of biological chemistry, 288(49), 35581–35591. https://doi.org/10.1074/jbc.M113.512046.
   4. Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., Pirro, V., Wainscott, D. B., Willard, F. S., Abernathy, M., Morford, L., Du, Y., Benson, C., Gimeno, R. E., Haupt, A., & Milicevic, Z. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and fat loss: From discovery to clinical proof of concept. Cell metabolism, 34(9), 1234–1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013.
   5. Neter, J. E., Stam, B. E., Kok, F. J., Grobbee, D. E., & Geleijnse, J. M. (2003). Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension (Dallas, Tex.: 1979), 42(5), 878–884. https://doi.org/10.1161/01.HYP.0000094221.86888.AE.
   6. Bacon, S. L., Sherwood, A., Hinderliter, A., & Blumenthal, J. A. (2004). Effects of exercise, diet and weight loss on high blood pressure. Sports medicine (Auckland, N.Z.), 34(5), 307–316. https://doi.org/10.2165/00007256-200434050-00003.
   7. Fantin, F., Giani, A., Zoico, E., Rossi, A. P., Mazzali, G., & Zamboni, M. (2019). Weight Loss and Hypertension in Obese Subjects. Nutrients, 11(7), 1667. https://doi.org/10.3390/nu11071667.